What are the potential harms of administering Alteplase for patients with AIS who harbor an intra-axial intracranial neoplasm?
Alteplase treatment for patients with AIS who harbor an intra-axial intracranial neoplasm is potentially harmful and should not be administered. Clinicians should also be informed of the indications and contraindications from local regulatory agencies (for current information from the US Food and Drug Administration refer to http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/103172s5203lbl.pdf). For a detailed discussion of this topic and evidence supporting these recommendations, refer to the American Heart Association (AHA) scientific statement on the rationale for inclusion and exclusion criteria for IV alteplase in AIS.14